| Item type |
学術雑誌論文 / Journal Article_02(1) |
| 公開日 |
2025-05-16 |
| タイトル |
|
|
タイトル |
Combined approach for predicting the efficacy of nivolumab in head and neck carcinoma by tissue and soluble expressions of PD-L1 and PD-L2 |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
主題Scheme |
Other |
|
キーワード |
head and neck carcinoma |
| キーワード |
|
|
主題Scheme |
Other |
|
キーワード |
nivolumab |
| キーワード |
|
|
主題Scheme |
Other |
|
キーワード |
programmed cell death ligand‐1 |
| キーワード |
|
|
主題Scheme |
Other |
|
キーワード |
programmed cell death ligand‐2 |
| キーワード |
|
|
主題Scheme |
Other |
|
キーワード |
soluble forms |
| 資源タイプ |
|
|
資源タイプ |
journal article |
| アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
| 著者 |
Ryosuke, Sato
Hiroki, Komatsuda
Takahiro, Inoue
Risa, Wakisaka
Michihisa, Kono
Hidekiyo, Yamaki
Kenzo, Ohara
Takumi, Kumai
Kan, Kishibe
Tatsuya, Hayashi
Miki, Takahara
|
| bibliographic_information |
en : Head and neck
巻 46,
号 9,
p. 2233-2243,
発行日 2024-04-26
|
| ISSN |
|
|
収録物識別子タイプ |
PISSN |
|
収録物識別子 |
1043-3074 |
| ISSN |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
1097-0347 |
| DOI |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1002/hed.27787 |
| リンクURL |
|
|
内容記述タイプ |
Other |
|
内容記述 |
https://onlinelibrary.wiley.com/doi/10.1002/hed.27787 |
|
言語 |
en |
| item_1716186501932 |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
PMID |
|
|
関連識別子 |
38665131 |
| item_5_description_33 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Background: Predictive biomarkers for nivolumab in recurrent or metastatic head and neck squamous cell carcinoma (RMHNSCC) have not yet been established.
Methods: The tumor proportion score (TPS), combined positive score (CPS), and soluble forms of programmed cell death ligand-1 (PD-L1) and programmed cell death ligand-2 (PD-L2) were retrospectively analyzed in patients with RMHNSCC treated with nivolumab.
Results: The positivity rates for TPS (PD-L1), CPS (PD-L1), TPS (PD-L2), and CPS (PD-L2) were 73.8%, 78.2%, 56.4%, and 78.2%, respectively. Patients with high TPS (PD-L1), CPS (PD-L1), or CPS (PD-L1 and PD-L2) showed significantly prolonged progression-free survival. Favorable overall survival was associated with high CPS (PD-L1 and PD-L2) and low soluble PD-L1 and PD-L2 levels. The expressions of tissue and soluble PD-L1/2 were not correlated.
Conclusions: Our study revealed that compared to PD-L1 expression alone, dual expression of PD-L1 and PD-L2 in tissue or soluble form could be feasible biomarkers in patients with RMHNSCC who received nivolumab |
|
言語 |
en |
| 出版タイプ |
|
|
出版タイプ |
AM |
| item_5_textarea_42 |
|
|
|
en |
|
|
© 2024 Wiley Periodicals LLC. |
38665131.pdf (1.1 MB)
